|Esomeprazole magnesium||proton pump inhibitor|
Naproxen/esomeprazole magnesium (Vimovo) is a pain reliever in the form of a tablet for oral consumption, with delayed release of esomeprazole magnesium, "a stomach acid–reducing proton pump inhibitor (PPI)" and naproxen, produced by AstraZeneca. Vimovo is FDA approved for use for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It is intended to decrease the risk of gastric ulcers from treatment with nonsteroidal anti-inflammatory drugs.
Vimoco was acquired by the Ireland-based company, Horizon Pharma on November 19, 2013. AstraZeneca retained "ex-U.S. rights to VIMOVO".
In a June 2017 article in The Atlantic, journalist Marshall Allen wrote that, the cost of Aleve and Nexium, the two common medications" that became the specialty drug Vimovo, was $40 a month. Horizon Pharma bills insurance companies $3,252 a month for Vimovo. According to The Atlantic, "since 2014, Horizon Pharma’s net sales have been more than $455 million".
- "Horizon Pharma Announces Agreement to Acquire U.S. Rights to VIMOVO(R) and Provides 2014 Guidance". Horizon Pharma, Inc. Deerfield, Illinois. November 19, 2013.(NASDAQ: HZNP)
- "Vimovo-Astrazeneca". felleskatalogen.no.
- "VIMOVO® (naproxen and esomeprazole magnesium) Tablets". Horizon Pharma. nd. Retrieved June 20, 2017.
- Allen, Marshall (June 20, 2017). "How Two Common Medications Became One $455 Million Specialty Pill". The Atlantic. Retrieved June 20, 2017.
After I was prescribed a brand-name drug I didn’t need and given a coupon to cover the out-of-pocket costs, I discovered yet another reason why Americans pay too much for health care.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|